Travere reports Q3 net loss $54.8M; FILSPARI sales $35.6M, full FDA approval in IgAN

Travere Therapeutics, Inc.

2024-Q3 EPS reported -$3.37 revenue$158,388,000

Net product sales $61.0M (FILSPARI $35.6M); 505 new PSFs in Q3; 2,989 total since launch.
Full FDA approval for FILSPARI in IgAN on Sept 5, 2024; broader label and orphan exclusivity to 2031.
R&D $51.7M, SG&A $65.6M; net loss $54.8M ($0.70/share); cash $277.4M.
sNDA submitted to modify liver monitoring; Type C meeting with FDA scheduled for FSGS path.
Voluntary halt of enrollment in Phase 3 HARMONY (pegtibatinase) due to manufacturing scale-up; restart expected 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.